Lexicon Pharmaceuticals: Buy Rating Backed by Promising Cardiovascular and Neuropathic Pain Advances

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pharmaceuticals today and set a price target of $4.00.

Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the potential of Lexicon Pharmaceuticals’ product, sota, in cardiovascular settings. The recent data from the SOTA-P-CARDIA study demonstrates selective modulation of epicardial adipose tissue (EAT), which supports the drug’s ability to improve cardiac structure and function in non-diabetic patients with heart failure with preserved ejection fraction (HFpEF). These findings suggest significant benefits for patients, enhancing the competitive profile of sota in treating both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM).
Furthermore, the advancement of pilavapadin towards late-stage evaluation in diabetic peripheral neuropathic pain (DPNP) is another key factor in Pantginis’s positive outlook. The promising results from the study, which include improvements in quality of life and functional capacity, reinforce the dual SGLT1/2 inhibition benefits of sota. These developments position Lexicon Pharmaceuticals favorably in the clinical and commercial landscape, underpinning Pantginis’s Buy recommendation.